Skip to main content

Where should you/can you publish your ChEMBL research?

Well, we've got to about 125 citations(1) for the main ChEMBL database paper so far, which for a year is a pretty good haul we think. Given this reasonably big number, we thought it would be appropriate to analyse where the use of ChEMBL makes it's way into the published literature - or what is our 'research user community'(2). A simple way to analyse this is to look at papers that cite ChEMBL, grouped by journal. The graph is below - it's a classic log-normal/power law style frequency-class distribution.

So J Chemical Information & Modelling (JCIM) is about 20% of all citations, and could indicate that the biggest early impact of ChEMBL is in the development of novel methods for compound design - which was one of our hopes for what our work and the ChEMBL data could achieve - better, safer drugs, quicker! Then there's the database community in Nucleic Acids Research (this is quite an unusual journal for comp chemists and modellers, but it is the de facto (and highest profile) place to publish "resource" papers in the life sciences, and it's a completely Open journal (3)) - so the data is being used and integrated elsewhere; then J Med Chem - the premier medicinal chemistry journal, and so on. It is also notable that ChEMBL has contributed centrally to two Nature full Articles this year (covered in earlier posts) - and given how infrequently chemistry makes the pages of the might Nature and Science this is great news for us, and probably good for the entire community with respect to profile and awareness of the field!!

It's interesting to see the strong trend to JCIM - this probably means that they have a receptive set of reviewers and know how to route stuff to the right people (of course if they then reject 95% of all ChEMBL citing papers that's not such good news).

So what next - it got us thinking about how we would expect ChEMBL to impact the field/literature long term - it's really really unlikely that papers that use methods and further integrated data and discover drugs will ever cite the ChEMBL NAR paper. But we will try and track the ripples that ChEMBL makes over time......

A few notes.
1) Citation data is from Google Scholar. But c'mon google - give us an API.
2) We know that many people who use ChEMBL are not really interested in publishing, that they are not free to publish their work, or that they don't have the time to publish, alongside all the other junk they have to deal with.
3) Open, Closed, Gold, Green, Good, Evil, Cow, Horse..... The ChEMBL NAR paper itself (the one that has the 125 citations analysed above) is Open Access, and the entire ChEMBL database team is solely funded by The Wellcome Trust (including my position), so we are under the obligations of their requirements for Open Access publishing. We cannot of course influence where researchers publish use of ChEMBL (and there are many publications that use the ChEMBL data that do not cite our papers :( ), but they will be under their own funders requirements - and remember that not all research is tax-payer (or similar) funded, so not all funders are as motivated to worry about Open Access, especially if it is yet an additional cost. So unfortunately, not all the papers that use ChEMBL are Open Access. But if you can, publish all your research and reviews Open Access - go on, it will make you smile and dogs in the street will like you!

Update - I've (jpo) done a bit of editing on this post overnight - I rushed it yesterday to catch a train, and thought that some additional context and comment was required.

jpo and francis

Comments

Popular posts from this blog

UniChem 2.0

UniChem new beta interface and web services We are excited to announce that our UniChem beta site will become the default one on the 11th of May. The new system will allow us to better maintain UniChem and to bring new functionality in a more sustainable way. The current interface and web services will still be reachable for a period of time at https://www.ebi.ac.uk/unichem/legacy . In addition to it, the most popular legacy REST endpoints will also remain implemented in the new web services: https://www.ebi.ac.uk/unichem/api/docs#/Legacy Some downtime is expected during the swap.  What's new? UniChem’s current API and web application is implemented with a framework version that’s not maintained and the cost of updating it surpasses the cost of rebuilding it. In order to improve stability, security, and support the implementation and fast delivery of new features, we have decided to revamp our user-facing systems using the latest version of widely used and maintained frameworks, i

A python client for accessing ChEMBL web services

Motivation The CheMBL Web Services provide simple reliable programmatic access to the data stored in ChEMBL database. RESTful API approaches are quite easy to master in most languages but still require writing a few lines of code. Additionally, it can be a challenging task to write a nontrivial application using REST without any examples. These factors were the motivation for us to write a small client library for accessing web services from Python. Why Python? We choose this language because Python has become extremely popular (and still growing in use) in scientific applications; there are several Open Source chemical toolkits available in this language, and so the wealth of ChEMBL resources and functionality of those toolkits can be easily combined. Moreover, Python is a very web-friendly language and we wanted to show how easy complex resource acquisition can be expressed in Python. Reinventing the wheel? There are already some libraries providing access to ChEMBL d

LSH-based similarity search in MongoDB is faster than postgres cartridge.

TL;DR: In his excellent blog post , Matt Swain described the implementation of compound similarity searches in MongoDB . Unfortunately, Matt's approach had suboptimal ( polynomial ) time complexity with respect to decreasing similarity thresholds, which renders unsuitable for production environments. In this article, we improve on the method by enhancing it with Locality Sensitive Hashing algorithm, which significantly reduces query time and outperforms RDKit PostgreSQL cartridge . myChEMBL 21 - NoSQL edition    Given that NoSQL technologies applied to computational chemistry and cheminformatics are gaining traction and popularity, we decided to include a taster in future myChEMBL releases. Two especially appealing technologies are Neo4j and MongoDB . The former is a graph database and the latter is a BSON document storage. We would like to provide IPython notebook -based tutorials explaining how to use this software to deal with common cheminformatics p

ChEMBL 30 released

  We are pleased to announce the release of ChEMBL 30. This version of the database, prepared on 22/02/2022 contains: 2,786,911 compound records 2,157,379 compounds (of which 2,136,187 have mol files) 19,286,751 activities 1,458,215 assays 14,855 targets 84,092 documents Data can be downloaded from the ChEMBL FTP site: https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_30/ Please see ChEMBL_30 release notes for full details of all changes in this release:  https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_30/chembl_30_release_notes.txt New Deposited Datasets EUbOPEN Chemogenomic Library (src_id = 55, ChEMBL Document ID CHEMBL4689842):   The EUbOPEN consortium is an Innovative Medicines Initiative (IMI) funded project to enable and unlock biology in the open. The aims of the project are to assemble an open access chemogenomic library comprising about 5,000 well annotated compounds covering roughly 1,000 different proteins, to synthesize at least

Multi-task neural network on ChEMBL with PyTorch 1.0 and RDKit

  Update: KNIME protocol with the model available thanks to Greg Landrum. Update: New code to train the model and ONNX exported trained models available in github . The use and application of multi-task neural networks is growing rapidly in cheminformatics and drug discovery. Examples can be found in the following publications: - Deep Learning as an Opportunity in VirtualScreening - Massively Multitask Networks for Drug Discovery - Beyond the hype: deep neural networks outperform established methods using a ChEMBL bioactivity benchmark set But what is a multi-task neural network? In short, it's a kind of neural network architecture that can optimise multiple classification/regression problems at the same time while taking advantage of their shared description. This blogpost gives a great overview of their architecture. All networks in references above implement the hard parameter sharing approach. So, having a set of activities relating targets and molecules we can tra